drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A fully human IgG1 anti-CD20 monoclonal antibody (brand name Kesimpta) that binds a distinct epitope on CD20 on mature B cells, inducing rapid and sustained B-cell depletion primarily via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, with possible direct apoptosis; spares hematopoietic stem cells and plasma cells.
nci_thesaurus_concept_id
C66952
nci_thesaurus_preferred_term
Ofatumumab
nci_thesaurus_definition
A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.
drug_mesh_term
Ofatumumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Fully human IgG1 anti‑CD20 monoclonal antibody that binds a distinct epitope on mature B cells and depletes them primarily via complement‑dependent cytotoxicity (CDC) and antibody‑dependent cellular cytotoxicity (ADCC), with possible direct apoptosis; spares hematopoietic stem cells and plasma cells.
drug_name
Ofatumumab
nct_id_drug_ref
NCT06345157